JP2013533867A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533867A5
JP2013533867A5 JP2013516930A JP2013516930A JP2013533867A5 JP 2013533867 A5 JP2013533867 A5 JP 2013533867A5 JP 2013516930 A JP2013516930 A JP 2013516930A JP 2013516930 A JP2013516930 A JP 2013516930A JP 2013533867 A5 JP2013533867 A5 JP 2013533867A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glutamine
dipeptide
source
organogel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013516930A
Other languages
English (en)
Other versions
JP2013533867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2011/050396 external-priority patent/WO2012000113A1/en
Publication of JP2013533867A publication Critical patent/JP2013533867A/ja
Publication of JP2013533867A5 publication Critical patent/JP2013533867A5/ja
Pending legal-status Critical Current

Links

Claims (8)

  1. ケロイド瘢痕を治療又は予防するための医薬を製造するための、グルタミン源の使用
  2. 前記グルタミン源が、L−アラニル−L−グルタミンを含むジペプチドである請求項1記載の使用
  3. 前記ジペプチドが、オルガノゲル中に懸濁されている請求項2記載の使用。
  4. 局所投与のための医薬組成物であって、グルタミン源を含む前記医薬組成物。
  5. 前記グルタミン源が、L−アラニル−L−グルタミンを含むジペプチドである請求項記載の医薬組成物。
  6. 前記ジペプチドが、医薬組成物の5〜25%w/wの割合で存在する、請求項5記載の医薬組成物。
  7. さらに、ビヒクルを含む請求項4〜6のいずれか1項記載の医薬組成物。
  8. 前記ビヒクルが、オルガノゲルを含む請求項記載の医薬組成物。
JP2013516930A 2010-06-28 2011-06-28 ケロイド治療 Pending JP2013533867A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35905310P 2010-06-28 2010-06-28
US61/359,053 2010-06-28
PCT/CA2011/050396 WO2012000113A1 (en) 2010-06-28 2011-06-28 Keloid treatment

Publications (2)

Publication Number Publication Date
JP2013533867A JP2013533867A (ja) 2013-08-29
JP2013533867A5 true JP2013533867A5 (ja) 2014-08-14

Family

ID=45401271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013516930A Pending JP2013533867A (ja) 2010-06-28 2011-06-28 ケロイド治療

Country Status (14)

Country Link
US (1) US20140005116A1 (ja)
EP (1) EP2585090A4 (ja)
JP (1) JP2013533867A (ja)
KR (1) KR20130089174A (ja)
CN (1) CN103002903B (ja)
AU (1) AU2011274224A1 (ja)
BR (1) BR112012033349A2 (ja)
CA (1) CA2804413A1 (ja)
CO (1) CO6680624A2 (ja)
HK (1) HK1183626A1 (ja)
MX (1) MX2013000107A (ja)
RU (1) RU2578426C2 (ja)
WO (1) WO2012000113A1 (ja)
ZA (1) ZA201209759B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
FR3004353B1 (fr) * 2013-04-10 2015-05-15 Fabre Pierre Dermo Cosmetique Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees
KR101800788B1 (ko) * 2017-03-31 2017-11-27 박영오 켈로이드 흉터 개선용 화장료 조성물
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
CN114767590B (zh) * 2022-04-20 2024-03-15 上海交通大学医学院附属第九人民医院 一种祛疤祛痘印美容液及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740409A (en) * 1980-08-22 1982-03-06 Mitsui Toatsu Chem Inc Remedy for disease caused by extraordinary propagation of collagen
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
WO2001014527A1 (en) * 1999-08-23 2001-03-01 Organogenesis Inc. Skin care compositions and treatments
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ppar−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
RU2234963C2 (ru) * 2002-09-16 2004-08-27 Сибирский государственный медицинский университет Способ лечения гипертрофических и келоидных кожных рубцов
CN103623390A (zh) * 2003-09-12 2014-03-12 科罗拉多州大学评议会 用于治疗损伤的谷氨酰胺
RU2275216C1 (ru) * 2004-12-08 2006-04-27 Елена Григорьевна Арий Способ профилактики формирования патологических кожных рубцов
DK1940439T3 (da) * 2005-08-11 2011-02-14 Univ Saskatchewan Nedsættelse af postoperativ adhæsionsdannelse med intraperitoneal glutamin
EP1947938A4 (en) * 2005-11-02 2009-07-01 Cpex Pharmaceuticals Inc MACROCYCLIC FORMULATIONS FOR TRANSMEMBRANE DRUG DELIVERY
CN100372522C (zh) * 2005-12-02 2008-03-05 何秋莎 护肤品
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine

Similar Documents

Publication Publication Date Title
JP2013533867A5 (ja)
PH12017501306A1 (en) Inhibitors of histone demethylases
IN2014DN09434A (ja)
PH12015501404B1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
JP2015525757A5 (ja)
PH12015500746A1 (en) Benzamides
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
WO2014043243A3 (en) Platinum compounds, compositions and methods for the treatment of cancer
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno
JP2013147480A5 (ja)
JP2017517574A5 (ja)
EA201590732A1 (ru) Диспергируемая таблетка
WO2015060702A8 (en) Pharmaceutical composition for controlling body mass gain comprising s-phenotropil
IN2014DN10683A (ja)
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
IN2013MU01251A (ja)